All In Biotech

Drug Trial Radar · NCT00333840

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,106

Actual

Start

Jun 2000

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • imatinib mesilateDrug

    imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.

  • interferon-alpha (INF-a)Drug

    interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.

  • cytarabine (ARA-C)Drug

    cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months

Locations

163 sites in 16 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Montgomery, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Berkeley, California

  • Novartis Investigative Site

    Campbell, California

  • Novartis Investigative Site

    Duarte, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Decatur, Illinois

  • Novartis Investigative Site

    Beech Grove, Indiana

  • Novartis Investigative Site

    Witchita, Kansas

  • Novartis Investigative Site

    Louisville, Kentucky

  • Novartis Investigative Site

    New Orleans, Louisiana

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Worcester, Massachusetts

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    East Lansing, Michigan

  • Novartis Investigative Site

    Minneapolis, Minnesota

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Billings, Montana

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Hackensack, New Jersey

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    Farmington, New Mexico

  • Novartis Investigative Site

    Buffalo, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Syracuse, New York

  • Novartis Investigative Site

    Chapel Hill, North Carolina

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.